Criteria | Details |
---|---|
Age | 18–70 |
Cirrhosis | Previous liver biopsy confirming histological features of cirrhosis |
Transient elastography (Fibroscan) >18 kPa | |
Clinical and radiological features that in the opinion of the investigator are in keeping with a diagnosis of cirrhosis | |
AST:Platelet Ratio Index (APRI) >2 | |
Aetiology of Liver Disease | Alcohol-related liver disease: Features (clinical, biochemical, histological or radiological) of chronic liver disease with a compatible history of alcohol excess (>80 g/day), in the absence of other causes of chronic liver disease Abstinent for ≥6 months prior to enrolment |
Chronic hepatitis C virus infection, positive HCV Antibody +/− PCR positive for HCV RNA Not currently on antiviral therapy | |
Chronic hepatitis B virus infection Positive HBsAg and Anti-HBC Established on antiviral therapy with adequate viral suppression | |
Primary biliary cirrhosis Two out of: cholestatic LFTs, positive AMA (>1:40),compatible histology If already receiving ursodeoxycholic acid: must be established on current dose >3 months prior to enrolment | |
Genetic haemochromatosis Diagnosis made on basis of compatible biochemistry (transferrin sat >60%, ferritin >400), genotype (homozygous C282Y or H63D, compound heterozygote) or Histology | |
Cryptogenic cirrhosis Diagnosis of cirrhosis unattributable to any other cause | |
Non-alcoholic fatty liver disease Either: histological evidence of steatosis in the absence of other liver diseases Or: Imaging compatible with NAFLD (eg Fatty infiltration of liver) and one or more risk factors (eg, elevated BMI, T2DM, hypertriglyceridaemia, hypertension) And: The absence of significant alcohol consumption (<20 g/day) and no evidence of other causes of chronic liver disease | |
α-1 anti-trypsin deficiency Diagnosis based on compatible genetic, phenotypic or histological testing | |
MELD score | 11.5–15.5 |
AMA, antimitochondrial antibody test; BMI, body mass index; HBC, hepatitis C virus; HBsAg, HBV surface antigen; T2DM, type 2 diabetes mellitus; LFTs, liver function tests; MELD, Model for End-stage Liver Disease.